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Summary The risk of subsequent second malignant neoplasm was studied in a cohort of 634 patients,
treated for a childhood cancer at the Gustave Roussy Institute between 1942 and 1969, and in complete
remission five years after diagnosis. The most frequent types of first primary cancers (FPC) were Wilms'
tumours (28% of the children), neuroblastomas (16%), lymphomas (12%) and soft tissue sarcomas (11%).
Median follow-up duration after FPC was 19 years. Thirty-two patients (obs=32) developed a total of 35
second cancers. Bone, thyroid, connective tissues and skin were the most frequent types of second cancer,
with six patients for each type. The average annual incidence of second cancer was 0.36%. The average
annual incidence for the periods 5-9, 10-14, 15-19, 20-24 and 25+ years after FPC was respectively 0.16%,
0.34%, 0.36%, 0.71% and 1.18%. The cumulative incidence of second cancer for the periods 5-20, 5-25 and
5-30 years after FPC was, respectively, 4.3% (95% Cl: 2.8-6.6%), 7.8% (95% Cl: 5.1-11.8%) and 13.0%
(95% CI: 8.2-20.0%). The expected number of cancers in the cohort, computed from Danish cancer incidence
data, was exp=2.2. When compared to this expected number, the average annual excess incidence of second
cancer, defined as obs-exp divided by the number of person years of observation, was 0.33%. This rose
from 0.15% for the period 5-9 years after FPC to 1.09% for the period beginning 25 years after FPC. The
standardised incidence ratio of second cancer (i.e. obs/exp) was 15 (95% CI: 10-21), and was fairly constant
in the period extending from 15 to 20 years after FPC diagnosis. Obs/exp was equal to 25 for the patients
who had had chemotherapy and equal to 9 for those who had not. Cyclophosphamide seemed less
carcinogenic than the other alkylating agents. Obs/exp was similar for the patients who had received
radiotherapy and for those who had not. The risk of cancer increased with age in the reference population
and increased faster in the cohort, because the standardised incidence ratio is constant over a long period.
Survivors of childhood cancer began to appear in the early
1940s and the proportion of long-term survivors has regu-
larly increased during the past 30 years. This improvement is
due to more intensive therapies. However, these more inten-
sive therapies may increase the risk of later complications
such as infertility, growth disturbances, deformities and
second primary malignant neoplasms.
The published results on the variation of the incidence of
second cancers with the time elapsed after first primary
cancer (FPC) treatment are contradictory. Estimation of the
25 years cumulative incidence of second cancer after child-
hood cancer varies from 1.7% (Potish et al., 1985) to 12.1%
(Tucker et al., 1984).
The present work reports the results of a cohort study
designed to evaluate the long-term risk of cancer according
to the time elapsed after FPC. This study was possible
because all the children seen between 1942 and 1969 at the
Gustave Roussy Institute (IGR) were treated and followed
actively by one of us (O.S.).
Materials and methods
Patients
The study included all of the 634 patients who were treated
at the IGR between 1942 and 1969 for a cancer in childhood
(age under 17), and who were alive and free of disease five
years after cancer diagnosis. The children who died or those
with active disease at five years after FPC diagnosis have not
been included because the risk of death from the first cancer
is very high during this period. None of these excluded
patients had developed a second malignancy neoplasm.
Information on treatment was abstracted from medical and
technical records of IGR. The diagnoses of first and second
malignant neoplasms were confirmed by histology, cytology
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or tumours markers, in the great majority, or by review of
medical records when a tumour sample was not available
(brain tumours, for instance). Histiocytosis and fibromatosis
were not considered as cancer.
Characteristics of the cohort are reported in Table I.
Among the 634 patients, 70 developed distant metastasis, 146
had loco-regional relapses and two had both metastasis and
loco-regional relapses during the 5 years after diagnosis of
the first cancer. By definition of the cohort, all were free of
disease five years after FPC diagnosis. Table II shows that
the most frequent types of first cancer were Wilms' tumour
(28%) and neuroblastoma (16%). Table III shows that
nearly 80% of the children received radiotherapy and half
received chemotherapy. Details of the chemotherapy and
radiotherapy are given in Table IV and in Table V,
respectively.
Statistical methods
The period of risk of a second cancer was defined as
beginning five years after the diagnosis of the first cancer
and ending at the time of the first of the following events:
occurrence of second cancer. death, loss to follow-up or I
Table I Characteristics of the 634 patients of the cohort
Characteristics
Calendar year of first cancer treatment:
median (range) 1965 (1942-69)
Sex ratio (M/F) 1.07
Age at first cancer treatment in years:
median (range) 3 (0 17)
Years of follow-up after first cancer
diagnosis: median (range) 19 (5-43)
Number of patients with second primary
cancers 32
Delay between first and second cancer in
years: median (range) 17 (7-31)
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Table II Number of second malignant neoplasms by type of first cancer
Second malignant neoplasms
Type offirst cancer Connective
(number ofpatients) Bone Thyroid tissue Brain Leukaemia Breast Skin Others Total
Wilms' tumour (175) 1 - 1 1 - - - 3
Neuroblastoma (99) - 3 1 - 1 2 7
Soft tissue sarcoma (71) 1 1 2 1 1 6
Lymphoma
Hodgkin's Disease (39) - - 1 - 1 1 2 5
Other lymphomas (34) 1 1 - - 2
Bone
Ewing's sarcoma (21) 2 - 1 3
Osteogenic sarcoma (18) - - - - 0
Brain tumour (81) - 1 _1 2 - 4
Gonadal tumour (29) - - - - - 0
Thyroid carcinoma (22) - - - 1 - 1
Retinoblastoma
Unilateral retin. (10) - - - 0
Bilateral retin. (10) 1 - - -1
Others (25) - - - 1 1 1 3
Total (634) 6 6 6 3 2 3 4 5 35a
aThree patients developed two second cancers: a thyroid carcinoma and an undifferentiated sarcoma of the mediastin after a
rhabdomyosarcoma as FPC, a carcinoma of the parotid and a breast phyllod sarcoma after a Hodgkin's disease as FPC, and two basocellular
carcinomas of the skin after a ganglio-neuroblastoma as FPC.
Table III Treatment received by the 634 children for the first
primary cancer (number of children treated by surgery for each
category)
Radiotherapy
No Yes Total
Chemotherapy No 57 (57) 264 (191) 321 (248)
Yes 49 (45) 264 (219) 313 (264)
Total 106 (102) 528 (410) 634 (512)
Table IV Description of chemotherapies administrated for first
primary cancer
Dose (mgm-2)
Number of
Type of drug childrena Median (Range)
Any alkylating agent 126
Cyclophosphamide 101 4,200 (250-70,000)
Procarbazine 22 6,350 (800-27,000)
Melphalan 8 100 (45-1,800)
Other alkylants 6
Any non-alkylating agents 225
Dactinomycin 164 2.7 (0.1-26.7)
Vincristin 112 12 (1-57)
Methotrexate 27 560 (933-4,500)
Vinblastin 23 138 (24-662)
Nitrogen mustard 18 72 (8-154)
Other non-alkylants 30
Any drugs 313
a132 children have received more than one drug; bIUm-2.
Table V Type of radiotherapy for first prim-
ary cancer
Number of
Type of energy childrena
Orthovoltage
Cobalt-60
High energy X-rays
Electrons
Brachytherapy
Unknown
250
172
101
37
16
9
Any type of radiotherapy 528
aFifty-five children were treated by more than
one type of energy.
January 1987. The cumulative incidence of second cancer
was estimated by the Kaplan-Meier method (Kaplan &
Meier, 1958). Prognostic factors of second cancer occurrence
were identified using the Cox regression model (Cox, 1972).
Since there is no national cancer registry in France and since
regional registries contain no incidence data before 1975,
expected numbers of cancer by sex, age and calendar year
were obtained from the Danish Cancer Registry for the
period 1953-82. The excess of incidence was computed as the
difference between the observed number of second cancer
(obs) and the expected number (exp), divided by the number
of person-years of observation (PY). The standardised inci-
dence ratio of second cancer was defined as the ratio
between the observed and the expected numbers of cancers
(obs/exp). Confidence intervals of the standardised incidence
ratios were calculated using exact Poisson probabilities. All
confidence intervals (CI) reported in this work are 95%
confidence intervals.
Results
A total of 107 patients (17%) were lost to follow-up before
January 1982 and 263 patients (41%) were lost before
January 1987. Median follow-up after the diagnosis of the
first cancer was 19 years (range 5-43).
Thirty-five second cancers were observed in 32 patients.
The most frequent sites of second cancers were bone,
thyroid, connective tissue and skin (Table II). Among the six
second cancers of the skin, one was a malignant melanoma,
the five others being basocellular carcinomas.
Overall incidence of second cancers
The mean annual incidence of second cancer was 7 times
greater 25 years or more after FPC diagnosis than 5-9 years
after FPC (i.e. 1.18%/0.16%) (Table VI). The cumulative
incidence of second cancer was 4.3% (CI: 2.8-6.6%) 20 years
after FPC diagnosis, 7.8% (CI: 5.1-11.8%) 25 years after,
and 13.0% (CI: 8.2-20.0%) 30 years after (Figure 1). Exclud-
ing the five second basocellular carcinomas of the skin, these
rates are, respectively, 4.2, 6.7 and 9.6%. Neither FPC
related events (metastases or locoregional relapses) nor sex
were found to have a significant influence on the risk of
second cancer.
From the Danish cancer incidence data, 2.2 cancers were
expected in the cohort during the follow-up period
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Table VI Observed and expected number of second malignant neoplasms (SMN) by five-year periods after the diagnosis
of first cancer
Number of Person-years Incidence of SMN Standardised
Years patients at risk Number of SMN incidence
after at the during the Annual Annual ratio
first beginning period Observed Expecteda incidence excess of SMN
cancer ofperiod (PY) (0) (E) (O/PY) ((O-E)/PY) (O/E)
5-9 634 3,046 5 0.36 0.16% 0.15% 13.9
10-14 576 2,677 9 0.46 0.34% 0.32% 19.6
15-19 505 1,936 7 0.56 0.36% 0.34% 12.5
20-24 257 846 6 0.42 0.71% 0.66% 14.3
25+ 99 424 5 0.39 1.18% 1.09% 12.8
5+ 634 8,929 32 2.19 0.36% 0.33% 15
aExpected numbers of cancers computed from the Danish Cancer Registry for the period 1953-82.
Age effect
The incidence of second cancer was 2.5 times greater for the
children aged over 5 years at FPC than for the younger
children, adjusting for the type of first cancer and on
treatment (P=0.02). Therefore, we stratified by age at FPC
while searching for other factors predictive of second cancer
occurrence.
When compared to the Danish incidence data, the stan-
dardised incidence ratio was similar for children aged 5 years
or more at FPC (obs/exp = 16, CI: 10-25) and for children
under 5 (obs/exp=12, CI: 6-22).
Type offirst cancer effect
The incidence of second cancer was 3.5 (P=0.04) times
lower after Wilms' tumours (Table VII) than after other
types of FPC, adjusting for the type of treatment.
When compared to the Danish incidence data, obs/exp
Yearsaftrfirst cancer treatment was equal to 5 (CI: 1-16) after Wilms' tumours and to 18
(Cl: 12-25) after the other tvnes of FPC (P=0.05V
Figure 1 Cumulative incidence of second cancers and 95%
confidence intervals in a cohort of 634 long-term survivors after
first primary cancer.
increased from 0.15%, 5-9 years after FPC, to 1.09% 25
years or more after FPC. The mean standardised incidence
ratio of second cancer was 15 (CI: 10-21), and was stable
over time after FPC diagnosis. When excluding second
basocellular carcinomas of the skin, for which incidence data
are considered as incomplete, this ratio was 13 (CI: 9-19),
and stable in the period from 15-30 years after FPC.
Types of second cancers
Six patients developed a thyroid cancer as second cancer,
five male and one female; all six had been given radio-
therapy and two had had chemotherapy for their FPC. The
cumulative incidence of second thyroid cancer was 1.16%
(CI: 0.6-3.9%), 25 years after FPC. Six patients developed a
bone sarcoma as second cancer, four male and two female;
all had been given radiotherapy and five had had chemo-
therapy for their FPC. The cumulative incidence of second
bone sarcoma was 0.9% (CI: 0.1-2.1%), 25 years after FPC.
Six patients developed a sarcoma of connective tissue, two
males and four females; five had received radiotherapy and
chemotherapy and one had been given chemotherapy alone.
These six patients corresponded to a cumulative incidence of
1.0% (CI: 0.4-2.4%). Only two cases of leukaemia (one
ALL and one LAM) were observed as second malignancies
in two men who had received chemotherapy, one of whom
had also been given radiotherapy for their FPC. These two
cases of leukaemia corresponded to a cumulative incidence
of 0.8% (CI: 0.2-3.2%) 25 years after FPC.
When compared to the Danish incidence data, the stan-
dardised incidence ratio (obs/exp) was equal to 137 (CI: 50-
298) for thyroid cancer, 77 (CI: 28-168) for bone sarcoma,
nine (CI: 1-33) for leukaemia, and 150 (CI: 55-326) for
connective tissue sarcoma.
Treatment effect
Of the 57 children treated by surgery alone (which is the
reference category for the study of the effect of radiotherapy
and chemotherapy), only one developed a SMN. This leads
to an estimation of the risk of second cancer which has a
large variability in this reference group. Radiotherapy
(globally or by type of energy) was not found to have an
effect on the overall risk of second cancer, but we did not
study the effect of the dose. The incidence of second cancer
was 3.4 times greater for children who received chemo-
therapy than for the other children, adjusting for the type of
FPC (Wilms' tumour versus other types) (P=0.001). The 93
children who had received cyclophosphamide as only alkyl-
ant had a risk of second cancer similar to the 187 who
received only non-alkylating agents. The 33 children treated
by alkylating agents other than cyclophosphamide had a
higher risk of second cancer than the children treated by
other chemotherapy (Table VII). The risk of second cancer
was not found to be associated with the total duration of
chemotherapy.
Table VII Relative risk (RR) of second malignant neoplasm after
first primary cancer (FPC) treatment (Cox's regression model with
stratification by age at FPC diagnosis)
Characteristics N RR (95 0 C1) P
FPC type
Wilms' tumour 175 1.0a
Others 459 3.8 (1.1-13.0) 0.04
Chemotherapy
No chemotherapy 321 1.Oa
Non-alkylants or
cyclophosphamide 280 2.9 (1.3- 6.6) 0.01
Alkylants (excluding
cyclophosphamide) 33 7.4 (2.8-21.7) <0.001
aReference category.
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When compared to the Danish incidence data, obs/exp
was similar for children who had received radiotherapy (15,
CI: 10-22) and for whose who had not (12, CI: 3-32). Obs/
exp was equal to 25 (CI: 15-40) for children who had
received chemotherapy (any type), to 67 (CI: 24-145) for
patients who had been given at least one alkylating agents
other than cyclophosphamide, to 20 (CI: 10-34) for those
who had received only cyclophosphamide or non-alkylating
agents, and to nine (CI: 5-15) for children who had not
received chemotherapy.
Discussion
With a long-term follow-up after FPC treatment, we found
that the standardised incidence ratio of second cancer after a
first cancer in childhood is constant over time between 5 and
30 years after FPC. It seems also that fewer second cancers
occur after Wilms' tumour than after other types of first
cancer and that cyclophosphamide is less carcinogenic than
other alkylating agents.
Taking 1 January 1987 as the end of the study, we found
a 25-year cumulative incidence of second cancer after FPC
equal to 7.8%. As compared to the Danish incidence data,
we found a standardised incidence ratio of 15 (13, when
excluding basocellular carcinoma of the skin as second
cancer) constant over the time elapsed since FPC treatment.
If study had been stopped in January 1982, the percentage of
patients lost to follow-up would have been 17%, the median
follow-up would have been equal to 16 years, 21 second
cancers would have been observed, the 25-year cumulative
incidence of second cancer would have been equal to 7.7%.
However, the standardised incidence ratio would remain
constant and equal to 14. Therefore, our results do not seem
to depend strongly on the high percentage (41%) of children
lost to follow-up before January 1987.
We used the data from the Danish Cancer Registry to
compute the expected number of second cancers in the
cohort. The median age of the patients in our cohort was 25
years at 1 January 1987. For this age group, cancer mor-
tality (and probably incidence) rates are similar for French
and Danish males. The cancer mortality rates for French
females are two-thirds of the rates for Danish females. It is
therefore possible that the expected number of second
cancers was overestimated. This would lead to an under-
estimation of the annual excess of incidence of second cancer
and of the standardised incidence ratio.
The distribution of the FPC types in our cohort is
different from that of other studies. In our cohort, more
Wilms' tumours and more neuroblastomas were observed
than in other studies on second malignancies after cancer in
childhood (Tucker et al., 1984; Hawkins et al., 1987).
Conversely, we observed fewer brain tumours and fewer
retinoblastomas and there were no cases of leukaemia. This
is due to the referral pattern of our cancer centre.
It is very difficult to compare our results with those of
other studies because the types of FPC, the calendar years of
FPC diagnosis, the age at FPC diagnosis, the treatments and
the length of follow-up are different. All these factors
influence the risk of second cancer. Because the incidence of
second cancers increases more or less exponentially with age
and follow-up time, one cannot compare mean annual
incidences and mean annual excesses of incidence in different
studies; both depend directly on the length of the follow-up
and on the age at FPC diagnosis. The cumulative incidence
is a function of the length of follow-up and depends on age
at FPC. The standardised incidence ratio by 5-year periods
seems to be the best index because it controls for age at FPC
and for length of follow-up.
Some authors define the period of risk of second cancer as
beginning earlier than 5 years after FPC diagnosis. For these
studies we have recomputed, when possible, the standardised
incidence ratio for the period beginning 5 years after FPC
diagnosis in order to enable comparisons with our results.
We will first compare our results to those from other
hospital-based studies, and, afterwards, to those from
registry-based studies.
The most important hospital-based cohort studied 13,000
3-year survivors of childhood cancer from 13 centres, includ-
ing our institution. With this cohort, and excluding baso-
cellular carcinomas of the skin, Tucker, for the Late Effect
Study Group (LESG), found a constant standardised inci-
dence ratio of 16, in agreement with our estimation of 13
(Tucker et al., 1984). Li, studying 410 5-year survivors from
the Sidney Farber Cancer Institute, found a standardised
incidence ratio of 20, not significantly different from our
estimation (Li et al., 1975; Li, 1977). However, standardised
incidence ratios by time periods after FPC diagnosis were
not published. One hospital-based study of 330 children
treated by radiotherapy observed a cumulative incidence of
second cancer of 1.7%, 25 years after FPC (Potish et al.,
1985). The standardised incidence ratio is not given, but one
can infer from the cumulative incidence that it was probably
smaller than 2.
The most important registry-based study, from the Child-
hood Cancer Research Group in Oxford, included 10,106 3-
year survivors from childhood cancer treated before 1979 in
the United Kingdom. With this registry, and excluding
basocellular carcinomas of the skin, Hawkins found a stan-
dardised incidence ratio of 6, less than half of our estimation
of 13, and constant over time after FPC diagnosis (Hawkins
et al., 1987). Olsen, with the data from the Danish Cancer
Registry, and excluding basocellular carcinomas of the skin,
found a standardised incidence ratio of second cancer of 2.5,
decreasing notably with time (Olsen, 1986).
In short, we observed a standardised incidence ratio of
second cancer after childhood cancer similar to other
hospital-based studies, and larger than registry studies.
One reason which might explain part of the difference
between registry-based and hospital-based studies is the
difference in treatment intensities. Between 1963 and 1972,
for instance, 38% of the children from the Danish Cancer
Registry received radiotherapy (Olsen, 1986), versus 82% in
our cohort; 36% received chemotherapy, versus 61% in our
cohort. Another problem could be the quality of follow-up
in hospital-based studies: it is quite possible that more
patients with relapse or second cancer come back to the
hospital for care, while healthier patients are more likely to
become lost to follow-up. Mike (1982), analysing the data
from the LESG cohort, used for each type of FPC a
theoretical expected follow-up time for survival after FPC,
estimated by a group of experts from the National Cancer
Institute. From these data, a standardised incidence ratio of
10 was found, decreasing with time after FPC treatment.
Under the assumption that children not known to have
developed a second cancer or to have died had survived and
remained disease-free through January 1987, we found a
standardised incidence ratio of 10, decreasing slightly from
13 to 8 over the time elapsed since FPC treatment.
Nevertheless, the assumption that no second malignant
neoplasms occur among patients lost to follow-up seems to
us to be too optimistic.
Our estimation of 77 (CI: 28-168) for the standardised
incidence ratio of second bone sarcomas is lower, but not
significantly so, than the LESG ratio of 133 (CI: 98-176)
(Tucker et al., 1987a). It is greater, but not significantly,
than the ratio of 43 (CI: 29-63) found by Hawkins (Hawkins
et al., 1987). When excluding genetic retinoblastomas as first
cancer, for which risk of second bone sarcoma is very high,
we found a standardised incidence ratio of 62 (CI: 21-146).
Tuker and Hawkins did not give ratios excluding genetic
retinoblastomas, but they may be estimated to be near, respec-
tively, 90 and 25. We found a standardised incidence ratio of
137 (CI: 50-298) for second thyroid cancers. This estimation
is not significantly larger than in the LESG (Tucker et al.,
1986), (obs/exp= 53, CI: 34-80), but is significantly larger
than in Hawkins (Hawkins et al., 1986), (obs/exp= 14, CI:
3-41). Our estimation of 150 (CI: 55-326) for the stan-
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dardised incidence ratio of second connective tissue sarcoma
is just significantly superior to that of the LESG (obs/
exp=41, CI: 25-63), and notably superior to that of
Hawkins (obs/exp= 15, CI: 6-33). Our estimation of 9 (CI:
1-33) for the standardised incidence ratio of second leukae-
mia is lower, but not significantly, than in the LESG (obs/
exp=28, CI: 18-52) (Tucker et al., 1987b), and larger, not
significantly, than in Hawkins (obs/exp=3.2, CI: 1.2-7.0).
This difference may be due to differences in treatment and in
follow-up methods, particularly for second thyroid carci-
nomas which may remain undetected for a long period of
time.
We found that patients treated for Wilms' tumour have a
lower risk of second cancer than patients with other types of
FPC (obs/exp of 5 vs. 18). The LESG (Tucker et al., 1984)
found a standardised incidence ratio after Wilms' tumour
significantly higher than we did, obs/exp=24, but Li et al.
(1983) did not (obs/exp=10).
It was not our purpose to study the exact relationships
between the risk of second cancer and FPC treatment or
FPC type. Such studies, which are in preparation, need case-
control analysis based on the comparison of the radio-
therapy dose delivered at the anatomical site of the develop-
ment of the second cancers, to that delivered at the same
anatomical sites for controls. We nevertheless consider that
there exists a lower carcinogenicity for cyclophosphamide
than for the other alkylating agents (mainly procarbazine
and melphalan). This result is in agreement with published
observations on survivors from ovarian cancers (Greene et
al., 1986), and on survivors from myelomatosis (Cuzick et
al., 1987), that melphalan is more leukaemogenic than
cyclophosphamide.
In conclusion, our study shows that the cumulative risk of
second cancers increases with time as a consequence of a
constant standardised incidence ratio and of the increase in
age of the survivors after childhood cancer. A man of the
general population aged 25 years (present median age of the
studied survivors) has an annual risk of cancer close to 45
per 100,000 person years, but at age 35 this risk is 90, and at
age 45 it is over 200. Assuming a standardised incidence
ratio constant and equal to 15, the risk of second cancer for
the survivors of our cohort will be 1,350 per 100,000 person
years when they would be 35 years old and 3,000 at 45.
These risks show the need for less aggressive treatment,
when possible, and for careful follow-up of cancer survivors.
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